Novel Immunobiologics for Psoriasis

Overview

Journal Indian J Pharmacol

Specialty Pharmacology

Date 2009 Dec 31

PMID 20040934

Authors

Nilanjan Ghosh

P N Singh

Vikas Kumar

Affiliations

Soon will be listed here.

Abstract

Psoriasis is one of the most common human skin diseases and is considered to have key genetic contributions. It is characterized by excessive growth and aberrant differentiation of keratinocytes, but is reversible with appropriate therapy with the possibilities of recurrence. The trigger of the keratinocyte response is thought to be the activation of the cellular immune system with T cells, dendritic cells and various immune related cytokines and chemokines being implicated in pathogenesis. Immunosuppressants like cyclosporine and methotrexate were used earlier in the treatment of psoriasis, however their use was associated with severe adverse effects due to down regulation of immune system. The most recent advances in therapies for psoriasis target specific immune components of psoriasis and promise to have high therapeutic efficacy with low adverse effects. This review focuses on the novel therapies aimed to specifically modulate the dysregulated immune system with minimal adverse effects.

References

Helms C, Cao L, Krueger J, Wijsman E, Chamian F, Gordon D . A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet. 2003; 35(4):349-56. DOI: 10.1038/ng1268. View

Lebwohl M, Tyring S, Hamilton T, Toth D, Glazer S, Tawfik N . A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003; 349(21):2004-13. DOI: 10.1056/NEJMoa030002. View

Thomas V, Yang F, Kvedar J . Biologics in psoriasis: a quick reference guide. J Am Acad Dermatol. 2005; 53(2):346-51. DOI: 10.1016/j.jaad.2005.04.011. View

Bachelez H, Flageul B, Dubertret L, Fraitag S, Grossman R, Brousse N . Treatment of recalcitrant plaque psoriasis with a humanized non-depleting antibody to CD4. J Autoimmun. 1998; 11(1):53-62. DOI: 10.1006/jaut.1997.0175. View

Wingren A, Parra E, Varga M, Kalland T, Sjogren H, Hedlund G . T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol. 1995; 15(3-4):235-53. DOI: 10.1615/critrevimmunol.v15.i3-4.30. View

Hochberg M, Lebwohl M, Plevy S, Hobbs K, Yocum D . The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005; 34(6):819-36. DOI: 10.1016/j.semarthrit.2004.11.006. View

Krueger J . The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002; 46(1):1-23; quiz 23-6. DOI: 10.1067/mjd.2002.120568. View

Garcia Aparicio A, Munoz-Fernandez S, Bonilla G, Miralles A, Cerdeno V, Martin-Mola E . Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Glück et al. Arthritis Rheum. 2003; 48(6):1764-5; author reply 1765-6. DOI: 10.1002/art.11019. View

Morris J, Waldmann T . Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis. 2000; 59 Suppl 1:i109-14. PMC: 1766615. DOI: 10.1136/ard.59.suppl_1.i109. View

10.

Gottlieb A, Matheson R, Lowe N, Krueger G, Kang S, Goffe B . A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003; 139(12):1627-32. DOI: 10.1001/archderm.139.12.1627. View

11.

Mehlis S, Gordon K . The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003; 49(2 Suppl):S44-50. DOI: 10.1016/s0190-9622(03)01134-4. View

12.

Gordon K, Bonish B, Patel T, Leonardi C, Nickoloff B . The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol. 2005; 153(5):945-53. DOI: 10.1111/j.1365-2133.2005.06816.x. View

13.

Greaves M, Weinstein G . Treatment of psoriasis. N Engl J Med. 1995; 332(9):581-8. DOI: 10.1056/NEJM199503023320907. View

14.

Liberopoulos E, Drosos A, Elisaf M . Exacerbation of tuberculosis enteritis after treatment with infliximab. Am J Med. 2002; 113(7):615. DOI: 10.1016/s0002-9343(02)01205-6. View

15.

Gottlieb A, Chamian F, Masud S, Cardinale I, Abello M, Lowes M . TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005; 175(4):2721-9. DOI: 10.4049/jimmunol.175.4.2721. View

16.

Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W . Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med. 2002; 9(1):40-6. DOI: 10.1038/nm804. View

17.

Wang F, Lee E, Lowes M, Haider A, Fuentes-Duculan J, Abello M . Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol. 2006; 126(7):1590-9. DOI: 10.1038/sj.jid.5700310. View

18.

Foss F . DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2001; 1 Suppl 1:S27-31. View

19.

Krueger G, Callis K . Development and use of alefacept to treat psoriasis. J Am Acad Dermatol. 2003; 49(2 Suppl):S87-97. DOI: 10.1016/mjd.2003.552. View

20.

Ten Hove T, van Montfrans C, Peppelenbosch M, van Deventer S . Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002; 50(2):206-11. PMC: 1773100. DOI: 10.1136/gut.50.2.206. View